Zonisamide improves motor function in Parkinson disease

  title={Zonisamide improves motor function in Parkinson disease},
  author={Miho Murata and Kazuko Hasegawa and Ichiro Kanazawa},
  pages={45 - 50}
Objective: To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD). Methods: We conducted a multicenter, randomized, double-blind, parallel-treatment, placebo-controlled study in Japan. Patients with PD who showed insufficient response to levodopa treatment were given placebo for 2 weeks and then treated for 12 weeks with 25, 50, or 100 mg/day of ZNS or placebo, in… 

Figures and Tables from this paper

Adjunct zonisamide to levodopa for DLB parkinsonism
This study provides Class I evidence that zonisamide (adjunctive to levodopa) improves parkinsonism and is well-tolerated in patients with DLB.
Zonisamide: in Parkinson's disease.
Zonisamide 25 mg once daily as adjunctive therapy with levodopa was generally well tolerated by patients with Parkinson's disease and was associated with increased striatal dopamine levels in animal models.
Zonisamide for the Treatment of Parkinson Disease: A Current Update
Based on adequate randomized controlled trials, zonisamide is considered a safe and efficacious add-on treatment in Parkinson disease and may play a beneficial role in improving non-motor symptoms in PD, including impulsive–compulsive disorder, rapid eye movement sleep behavior disorder, and dementia.
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials
The findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.
Zonisamide for the treatment of Parkinson’s disease
  • H. Miwa
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2007
It is expected that zonisamide will be safe and tolerated in patients with PD, as it has been used as an antiepileptic for more than 15 years; however, further studies are required to evaluate its safety and tolerability in the treatment of PD.
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data
Zonisamide significantly improved the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12.
Zonisamide for Essential Tremor
  • W. Ondo
  • Medicine
    Clinical neuropharmacology
  • 2007
Zonisamide significantly (albeit modestly) improved the TSGRS scores in this small group of medically refractory subjects who completed the evaluation, however, clinical impressions did not improve, and the study was complicated by a large dropout rate caused by subjective lack of efficacy and by AEs.


Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
  • M. Murata
  • Biology, Psychology
    Current pharmaceutical design
  • 2004
It is suggested that the activation of dopamine synthesis and the moderate level of MAOB inhibition are main mechanisms of ZNS effects on PD.
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD.
Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to
Effects of zonisamide on dopaminergic system
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity
Results support previously reported findings and provide additional evidence that the anticonvulsant ZNS appears to possess anti-Parkinson’s properties and could be a novel agent for the treatment of PD that could delay the use of or reduce the amount of levodopa needed to treat patients with PD.